comscoreImmunotherapy

Immunotherapy

17 Research news
 
 
Article
People Receiving Cancer Treatment Develop ‘Adequate’ Immune Response to Pfizer COVID-19 Vaccine

Nearly all the people in a clinical trial who were receiving systemic intravenous cancer treatment had an adequate immune response to the Pfizer-BioNTech COVID-19 vaccine.

 
Article
Tecentriq Approved as First Immunotherapy for Breast Cancer

On March 8, 2019, the FDA approved Tecentriq in combination with the chemotherapy medicine Abraxane to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.

Mar 8, 2019 | Diagnosis and Immunotherapy
 
Article
Immunotherapy for Early-Stage Triple-Negative Breast Cancer: Understanding What Appear to Be Conflicting Results

Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not.

 
Article
Immunotherapy Tecentriq Helps Treat Certain Advanced-Stage Triple-Negative Breast Cancers

Tecentriq, an immunotherapy medicine, combined with the targeted therapy Abraxane was better than Abraxane alone for people diagnosed with locally advanced or metastatic triple-negative breast cancer who had not been treated yet for advanced-stage disease.

 
Article
Studies Show Conflicting Results With Tecentriq and Chemotherapy for Metastatic Triple-Negative Breast Cancer

When treating locally advanced or metastatic triple-negative breast cancer for the first time, adding Tecentriq to Taxol did not improve survival, while adding Tecentriq to Abraxane did improve survival.

 
Article
Adding Keytruda to Chemotherapy Improves Overall Survival in Metastatic, Strongly PD-L1-Positive Triple-Negative Breast Cancer

Adding the immunotherapy medicine Keytruda to chemotherapy improved overall survival more than chemotherapy alone in people diagnosed with metastatic triple-negative, strongly PD-L1-positive breast cancer, according to the KEYNOTE-355 study’s final results.

 
Article
Adding Keytruda to Chemotherapy Before Surgery for Early-Stage, Triple-Negative Breast Cancer Improves Response to Treatment

The combination of the immunotherapy Keytruda and chemotherapy before surgery to remove early-stage, triple-negative breast cancer led to a better pathologic complete response than chemotherapy alone.

 
Article
Keytruda Plus Chemotherapy Offers More Benefits Than Chemo Alone as First Treatment for Metastatic Triple-Negative Breast Cancer With High Levels of PD-L1

Keytruda plus chemotherapy offered better progression-free survival than chemotherapy alone as the first treatment for metastatic triple-negative breast cancer or triple-negative breast cancer that has come back in the breast area but can't be removed with surgery, with high levels of the PD-L1 protein.

 
Article
Adding Tecentriq to Chemotherapy Before Surgery for Early-Stage Triple-Negative Breast Cancer Improves pCR Rates

Adding Tecentriq to chemotherapy before surgery for early-stage triple-negative breast cancer offered higher pathologic complete response rates than chemotherapy alone, no matter the PD-L1 status of the cancer.

 
Article
Experimental Immunotherapy Medicine Works Similarly in Black and White Women With Triple-Negative Breast Cancer

When more Black women diagnosed with early-stage, triple-negative breast cancer joined a study on Imfinzi, the results showed the immunotherapy was as effective in Black women as it was in women of other races and ethnicities.

Aug 5, 2022 | Diagnosis, Ethnicity and Immunotherapy
 
Article
Six Months After Second Pfizer Vaccine Dose, People With Solid Tumors Have Same COVID-19 Antibody Levels as People Without Cancer

Six months after receiving their second dose of the Pfizer COVID-19 vaccine, people diagnosed with solid tumor cancers had about the same antibody levels as people who hadn’t been diagnosed with cancer.

 
Article
Genentech Withdraws Breast Cancer Indication From Tecentriq

On Aug. 27, 2021, Genentech announced it is voluntarily withdrawing the breast cancer indication from the immunotherapy medicine Tecentriq in the United States.

Aug 28, 2021 | Diagnosis and Immunotherapy
 
Article
Keytruda Before and After Surgery Improves Outcomes in Early-Stage Triple-Negative Breast Cancer

The immunotherapy medicine Keytruda plus chemotherapy before surgery and Keytruda alone after surgery improved event-free survival better than chemotherapy alone in women diagnosed with early-stage triple-negative breast cancer.

 
Article
FDA Approves Keytruda for Early-Stage Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved Keytruda plus chemotherapy before surgery, followed by Keytruda alone after surgery to treat early-stage triple-negative breast cancer with a high risk of recurrence.

Jul 27, 2021 | Diagnosis and Immunotherapy
 
Article
Very Early Study Hints That Keytruda May Offer Benefits for Certain Metastatic HER2-Positive Breast Cancers

A very small, very early study hints that the immunotherapy medicine Keytruda may offer benefits for certain metastatic HER2-positive breast cancers.

 
Article
New Analysis Shows Immunotherapy Tecentriq Only Effective in PD-L1-Positive Breast Cancer

A new analysis of the IMpassion130 trial found that the immunotherapy Tecentriq (chemical name: atezolizumab) in combination with the chemotherapy Abraxane (chemical name: albumin-bound paclitaxel or nab-paclitaxel) only helps treat cancers that are PD-L1-positive.

 
Article
FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer

On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.